This study is looking at a new way to detect cancer cells after treatment in people with high-risk stage I, II, and III germ cell tumors (a type of cancer that starts in reproductive cells). Researchers will collect whole blood samples to look for circulating tumor DNA (ctDNA), which are tiny pieces of cancer DNA found in the blood. The goal is to see how well ctDNA can accurately identify if cancer cells are still present. You could be eligible if you are 18 years or older and have a confirmed diagnosis of seminomatous or non-seminomatous germ cell tumor. The study aims to enroll 130 participants, but its current recruitment status is unclear.

Study design

This is a specimen collection study that plans to enroll 130 participants. It is an interventional study, but the phase is not specified.

What's involved

You would provide whole blood samples for ctDNA testing at screening and every 4 months for up to 2 years.

Compensation

Not stated in the trial record.

Follow-up

You would be followed for up to 2 years after screening.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.